EACS 14 Brussels 2013

14th European AIDS Conference (EACS), 16-19 October 2013, Brussels

1 December 2013. Related: Conference reports.

Dolutegravir superior to darunavir/r at week 48 in open label treatment naïve study

1 December 2013. Related: Conference reports, Antiretrovirals.

GSK744: 24-week results with oral integrase inhibitor planned for once-monthly injections

1 December 2013. Related: Conference reports, Antiretrovirals.

Cenicriviroc: 48 week results compared to efavirenz

1 December 2013. Related: Conference reports, Antiretrovirals.

Approaches to once-daily raltegravir: new formulation likely to require food

1 December 2013. Related: Conference reports, Antiretrovirals.

DSMB stops boosted atazanavir monotherapy study due to virological failure

1 December 2013. Related: Conference reports, Antiretrovirals.

Caution against prolonged use of bisphosphonates in patients with mild-moderate fracture risk

1 December 2013. Related: Conference reports, Coinfections and complications.

Osteoporosis triples risk of later fracture in 1000-person US HIV group

1 December 2013. Related: Conference reports, Coinfections and complications.

Bone turnover marker changes early in ART predict bone loss after 96 week

1 December 2013. Related: Conference reports, Coinfections and complications.

Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison

1 December 2013. Related: Conference reports, Lipodystrophy and metabolic complications.

Classic risk factors, but not HIV, linked to arterial stiffness in middle-aged

1 December 2013. Related: Conference reports, Coinfections and complications.